Telehealth ketamine has attracted both excellent practitioners and regulatory casualties. This page documents the verifiable credentials, compliance practices, and clinical review process behind Discreet Ketamine. Every claim here can be independently verified through the linked state and federal databases.
Every prescription is reviewed and signed by Dr. Ben Soffer personally.
License number OS13821 — Active. Issued by the Florida Department of Health.
Verify at flhealthsource.govLicense number 25MB12957100 — Active. Issued by the New Jersey Board of Medical Examiners.
Verify at njconsumeraffairs.gov/bmeInternal Medicine — American Board of Internal Medicine (ABIM).
Verify at certificationmatters.orgActive DEA registration for Schedule II-V controlled substance prescribing in Florida and New Jersey. The DEA does not publish a public lookup for individual physicians; the DEA number is provided to the dispensing pharmacy on each prescription and is verifiable through the state pharmacy board.
Medication is sourced from a U.S.-licensed compounding pharmacy. We disclose the pharmacy on request before any prescription is filled.
Medication is compounded by a state-licensed, PCAB-accredited (Pharmacy Compounding Accreditation Board) U.S. pharmacy. Not imported, not gray-market, not from offshore suppliers. The dispensing pharmacy name, license number, and DEA registration are disclosed to every patient before the first prescription is filled.
Our pharmacy partner follows USP <795> (non-sterile compounding) and applicable USP <800> (hazardous drug handling) standards. PCAB accreditation indicates compliance above the regulatory minimum for compounding quality assurance.
How a patient moves from inquiry to prescription, and the safeguards along the way.
Every prospective patient completes a structured intake covering medical history, psychiatric history, current medications, cardiovascular history, and the standard contraindications (active psychosis, uncontrolled hypertension, recent cardiac events, untreated bipolar disorder, pregnancy, active substance use disorder). Approximately 10-15% of applicants are screened out at this stage and referred to alternative care.
Approved applicants schedule a 30-minute video consultation with Dr. Soffer. Full medical history is reviewed live. The treatment plan, dosing protocol, and after-hours protocol are discussed before any prescription is issued.
If at-home treatment is appropriate, Dr. Soffer signs the prescription and sends it electronically to the partner compounding pharmacy via DEA-approved e-prescribing infrastructure. The pharmacy dispenses and ships in discreet packaging.
Dr. Soffer remains the prescribing physician across the entire treatment course — there is no rotation between clinicians. Follow-up visits are included in every monthly plan. Patients have access to a physician contact within 24 hours for non-emergency questions and a documented escalation path for urgent issues.
All medical content on this site is reviewed by Dr. Soffer before publication. Articles include a "Medically reviewed by Ben Soffer, MD" byline with the review date. PubMed-indexed citations are used for clinical claims; marketing claims about efficacy follow FDA guidance for off-label compounded preparations.
How patient health information is handled, stored, and protected.
Patient communications, intake forms, and medical records are stored in HIPAA-compliant systems with encryption in transit and at rest. Business Associate Agreements (BAAs) are in place with all third-party processors that handle PHI (Protected Health Information).
We collect only the medical and contact information needed to evaluate eligibility, prescribe safely, and ship medication. We do not sell patient data. We do not use analytics tools that capture PHI on patient-portal pages.
Any patient testimonial published on this site has been authorized in writing by the patient under HIPAA-compliant consent forms. Testimonials describe patient experience and process — they do not make efficacy claims about compounded ketamine for off-label indications.
How DEA telehealth flexibilities apply, and how we operate within them.
Ketamine is a Schedule III controlled substance. Telehealth prescribing of controlled substances is governed by the Ryan Haight Act and DEA telehealth flexibilities, which have been repeatedly extended past their original COVID-era expiration. Dr. Soffer is registered with the DEA and licensed to prescribe Schedule II-V substances in Florida and New Jersey.
We prescribe only to patients physically located in Florida or New Jersey at the time of the consultation. We do not prescribe to patients traveling temporarily, located out of state, or based outside the U.S. State licensing rules require the physician-patient relationship to be established with appropriate documentation, and we maintain that documentation for every patient.
We monitor DEA and state telehealth rule changes continuously. If federal or state regulations change in ways that affect our practice, we notify patients before any disruption to their treatment. We do not adopt practices that depend on regulatory ambiguity.
We answer compliance and credential questions before your eligibility check, your consultation, or your first prescription. If something on this page isn't clear, ask before you decide.
For more on evaluating any online ketamine clinic — not just ours — see our physician's checklist.